The Latest Breaking News from ADMA Biologics

This biopharmaceutical firm specializes in treatments to prevent and treat infectious diseases.

In a stock market that favors the giants, it's still possible to reap big gains investing in Wall Street's small fries.

ADMA stock plummeted Thursday after the company's auditor unexpectedly resigned. But ADMA Biologics kept its guidance for this year and next.

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

The Chart of the Day belongs to the biomedical company ADMA Biologics (ADMA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.